Redcare Pharmacy stock gains 3.94 percent after guidance raise

Published on 10/06/2026 at 16:52 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Redcare Pharmacy stock reflects a second 2026 guidance increase, with total revenue growth now set at 16% to 18%. Four analysts set an average target of EUR 100.25.

Flatlay mit Aktienzertifikat, ISIN-Karte, Pillenblistern und Stethoskop von oben — Redcare Pharmacy (Shop Apoth), ISIN NL0012044747, zeigt Flatlay mit Aktienzertifikat, ISIN-Karte und markenfreien Apotheken-Utensilien, Illustration mit AI erstellt.

Redcare Pharmacy stock was trading at EUR 68.60 on Xetra on October 6, 2026, up 3.94% as the online pharmacy group’s latest guidance increase continued to shape sentiment. According to Redcare Pharmacy on September 28, 2026, the company raised its full-year revenue growth guidance for the second time in 2026.

Revenue guidance moves higher

Total revenue growth is now expected at 16% to 18%, compared with the previous range of 15% to 17%. The change gives investors a clearer numerical measure of the upgrade, while the adjusted EBITDA margin guidance remains at 2.5% to 3.0% for fiscal year 2026.

The strongest revision concerns Germany’s prescription business. Redcare lifted its full-year Rx revenue range to EUR 730 million to EUR 760 million from EUR 680 million to EUR 720 million, while the associated growth forecast rose to 45% to 51% from 35% to 43%, according to Redcare Pharmacy.

Analyst targets remain above market

The guidance revision has also influenced broker expectations ahead of the third-quarter update. On September 29, 2026, Deutsche Bank Research raised its Redcare Pharmacy target from EUR 103 to EUR 104 and retained a Buy rating, as reported by finanzen.at.

A broader view from finanzen.ch on October 3, 2026, showed four analysts recommending Buy and an average 12-month target of EUR 100.25. That average target lies 46.1% above the EUR 68.60 reference price, making the gap between current valuation and analyst expectations a central market question.

Third-quarter date is set

Redcare’s preliminary September Rx revenue in Germany grew 51% year over year, while the third quarter showed preliminary growth of 56%, according to the September 28 company release. These figures support the guidance change, but the full interim numbers will determine how much of the forecast improvement translated into reported revenue.

Redcare Pharmacy will publish its third-quarter 2026 interim statement on October 29, 2026, and hold its quarterly conference call on the same date, according to Redcare Pharmacy. For investors, the report will provide the next test of the 16% to 18% group growth outlook and the 45% to 51% German Rx growth range.

Stock gains after guidance raise

Redcare Pharmacy stock was trading at EUR 68.60 on Xetra on October 6, 2026, with a daily gain of 3.94%. The company is listed on Frankfurt’s Regulated Market in the Prime Standard and is a member of the SDAX.